Immunotherapy is the latest innovation for the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) entered the clinical practice and are under evaluation in clinical trials. MAbs can target highly selective and specific antigens on the cell surface of MM cells causing cell death (CD38 and CS1), convey specific cytotoxic drugs (antibody-drug conjugates), remove the breaks of the immune system (programmed death 1 (PD-1) and PD-ligand 1/2 (L1/L2) axis), or boost it against myeloma cells (bi-specific mAbs and T cell engagers). Two mAbs have been approved for the treatment of MM: the anti-CD38 daratumumab for newly-diagnosed and relapsed/refractory patients and the anti-CS1 elotuzumab in the relapse setting. These compounds are under investigation in clinical trials to explore their synergy with other anti-MM regimens, both in the front-line and relapse settings. Other antibodies targeting various antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a promising target and several compounds targeting it have been developed. Encouraging results have been reported with antibody drug conjugates (e.g., GSK2857916) and bispecific T cell engagers (BiTEs®), including AMG420, which re-directs T cell-mediated cytotoxicity against MM cells. Here, we present an overview on mAbs currently approved for the treatment of MM and promising compounds under investigation.

Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma

Bonello F.
First
;
Mina R.;Boccadoro M.;Gay F.
Last
2020

Abstract

Immunotherapy is the latest innovation for the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) entered the clinical practice and are under evaluation in clinical trials. MAbs can target highly selective and specific antigens on the cell surface of MM cells causing cell death (CD38 and CS1), convey specific cytotoxic drugs (antibody-drug conjugates), remove the breaks of the immune system (programmed death 1 (PD-1) and PD-ligand 1/2 (L1/L2) axis), or boost it against myeloma cells (bi-specific mAbs and T cell engagers). Two mAbs have been approved for the treatment of MM: the anti-CD38 daratumumab for newly-diagnosed and relapsed/refractory patients and the anti-CS1 elotuzumab in the relapse setting. These compounds are under investigation in clinical trials to explore their synergy with other anti-MM regimens, both in the front-line and relapse settings. Other antibodies targeting various antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a promising target and several compounds targeting it have been developed. Encouraging results have been reported with antibody drug conjugates (e.g., GSK2857916) and bispecific T cell engagers (BiTEs®), including AMG420, which re-directs T cell-mediated cytotoxicity against MM cells. Here, we present an overview on mAbs currently approved for the treatment of MM and promising compounds under investigation.
12
1
E15
N/A
https://www.mdpi.com/2072-6694/12/1/15
https://doi.org/10.3390/cancers12010015
Antibody products; B cell maturation antigens (BCMAs); Bispecific T cell engagers (BiTEs®); Immunotherapy; Monoclonal antibodies (mAbs); Multiple myeloma (MM)
Bonello F.; Mina R.; Boccadoro M.; Gay F.
File in questo prodotto:
File Dimensione Formato  
[Publisher Version] Bonello et al - 2019 - Therapeutic monoclonal antibodies and antibody products - cancers-12-00015-v2.pdf

Accesso aperto

Descrizione: [Published Version] Bonello F et al. Cancers (Basel) . 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. Open access article. Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Available at: https://www.mdpi.com/2072-6694/12/1/15/htm | https://doi.org/10.3390/cancers12010015
Tipo di file: PDF EDITORIALE
Dimensione 597.05 kB
Formato Adobe PDF
597.05 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1732783
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 24
social impact